ANTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
8.7M
-2.6%
8.9M
-15.6%
10.6M
+13.3%
9.3M
-7.2%
10.0M
R&D
5.7M
-4.9%
6.0M
-10.7%
6.7M
-2.0%
6.9M
-1.7%
7.0M
SG&A
2.9M
+2.1%
2.9M
-24.2%
3.8M
+56.3%
2.4M
-19.8%
3.0M
Operating Income
-8670000
+2.6%
-8904000
+15.6%
-10551000
-13.3%
-9316000
+7.2%
-10040000
EBITDA
-8670000
+2.6%
-8904000
+15.6%
-10551000
-13.3%
-9316000
+7.2%
-10040000
Net Income
-7957000
+2.8%
-8185000
+18.4%
-10028000
-15.1%
-8710000
+6.9%
-9353000
EPS (Basic)
$-0.17
+5.6%
$-0.18
+37.9%
$-0.29
+0.0%
$-0.29
+6.5%
$-0.31
EPS (Diluted)
$-0.17
+5.6%
$-0.18
+37.9%
$-0.29
+0.0%
$-0.29
+6.5%
$-0.31
Shares (Diluted)
46.1M
+3.0%
44.8M
+31.4%
34.1M
+12.2%
30.4M
+0.3%
30.3M
AN2 Therapeutics (ANTX) — Financials